Aptevo targets solid tumors with planned Nectin-4 x PD-L1 dual-targeting platform strategy
APVO•Planned applications
Planned applications include targeted radiopharmaceutical programs, T-cell engagers, and immune-modulating therapies aimed at improving tumor localization and anti-tumor immunity.
Aptevo outlines solid-tumor platform strategy
Aptevo set a new solid-tumor strategy built around a patent filing for a Nectin-4 x PD-L1 dual-targeting backbone.
The platform is intended to generate multiple future therapeutic candidates from one architecture, supporting pipeline expansion and partnering discussions.
